List of partners

The following companies and organisations will join the 31st ECNP Congress.

In alphabetical order:  

 

ABP - Brazilian Psychiatric Association
Stand number: 26

The Brazilian Psychiatric Association (ABP) is a non-profit organisation who acts in defense of psychiatric labor rights and development. ABP organises the Brazilian Congress of Psychiatry (CBP), the third major event in the world. ABP publishes the most important scientific magazine on the medical community of Latin America, the Revista Brasileira de Psiquiatria.
www.abp.org.br


  ABP 

Allergan Plc
Expert science exchange: CE.02

Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
www.allergan.com

  Allergan 

ANGELINI           
Stand number: 9
Satellite symposia: C.09 & C.12

Angelini is a privately held international pharmaceutical company. Founded in Italy in 1919, it has branches in 20 countries and employs 6,000 people. Angelini’s research is focused on nervous system diseases and disorders, infectious diseases, pain and inflammation.
www.angelini.it

 

   Angelini

BIOPAC Systems, Inc.
Stand number: 20

BIOPAC lets you measure physiology anywhere with innovative, compatible solutions that can be used by anyone for meaningful discovery. We make high-quality scientific tools for physiology measurement and interpretation with superior compatibility and world-class support. Empowering cutting edge tools that inspire discovery in ambulatory, MRI, lab, and real-world.
www.biopac.com

 

   Biopac

C2Care
Stand number: 25

Virtual reality in the service of health C2care designs therapeutic software based on virtual reality for all healthcare professionals. The main goal of this new comprehensive therapeutic tool is to treat patients with depression, phobias, addictions, eating disorders and balance disorders through through immersion bring by virtual reality.
www.c2.care

   

EPA - European Psychiatric Association
Stand number: 27

With active individual members in as many as 88 countries and 40 National Society/Association Members who represent more than 78,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development.
www.europsy.net

 

   EPA

EUFAMI
Stand number: 14

EUFAMI is an international NGO based in Belgium committed to improving the care and welfare for people with mental illness. Our mission is to represent at the European level all family members of persons that are affected by mental illness and to protect their rights and interests.
www.eufami.org

 

  EUFAMI 

GAMIAN-Europe
Stand number: 13

GAMIAN-Europe, a patient-driven pan-European organisation, representing the interests of persons affected by mental health illness and advocates for their rights. GAMIAN-Europe was established in 1998 as a representative coalition of patient organisations putting the patient at the centre of all issues of the EU healthcare debate.
www.gamian.eu

 

   GAMIAN

Gedeon Richter Plc.
Stand number: 8
Satellite symposium: C.10


Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. Its latest achievement in R&D is the original antipsychotic compound, cariprazine, already marketed in the US for bipolar mania and schizophrenia treatment and received marketing authorization in the EU for the treatment of schizophrenia.
www.richter.hu

 

  gedeon-richter 
Genomind
Stand number: 19

Genomind is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Genomind is a CLIA certified and CAP accredited laboratory.
www.genomind.com
 
  Genomind 

H. Lundbeck A/S
Stand number: 4
Satellite symposia: C.01, C.02, C.04, C.05 and C.13


Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind. Read more at www.lundbeck.com/global/about-us/progress-in-mind Connect with us on Twitter at @Lundbeck and via our LinkedIn company page.
www.lundbeck.com

 

   Lundbeck

JAMA Network
Stand number: 17

Building on a tradition of editorial excellence, the JAMA Network brings JAMA together with eleven specialty journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine. JAMA Network Open, a new open access, general medical journal, launched in 2018.
www.jamanetwork.com

 

   

Janssen Pharmaceutica NV
Stand number: 1
Satellite symposium: C.03 and C.06


At Janssen, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We collaborate with the world for the health of everyone in it.
Follow us at www.twitter.com/janssenEMEA
www.janssen.com

 

  Janssen

Massachusetts General Hospital
Stand number: 18

The MGH Clinical Trial Network and Institute is setting new standards in psychiatric clinical research by implementing trial methodologies and strategies designed to reduce placebo response. Our proprietary SAFER interview, innovative rater training, SPCD study design, and access to KOLs enable us to offer sponsors an unsurpassed track record in CNS studies.
www.mgh-Ctni.org

 

  Massachusetts General Hospital
 

Lundbeck Institute
Stand number: 4

Our mission is to develop and cascade unbiased, evidence-based medical education in psychiatry and neurology from leading experts to health care professionals and create a forum to facilitate knowledge-sharing. Since 1997 we have been committed to providing expert, international, interactive seminars, thereby building a valued legacy in medical education.
www.lundbeck.com

 

   Lundbeck Institute

NbN - Neuroscience-based Nomenclature
Stand number: 10

The Neuroscience-based Nomenclature (NbN) is an ECNP-led international collaboration established to align the nomenclature of psychotropic drugs with the neuroscience underlying them. The new nomenclature encompasses all medications with CNS indications and is now available to clinicians for free download on the iOS App Store and the Google Play Store.
http://nbnomenclature.org

 

  NBN logo new 2017 

Otsuka Pharmaceutical Europe Ltd
Stand number: 3
Satellite symposia: C.01

Otsuka Pharmaceutical Development and Commercialization, Inc
Satellite symposia C.13

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka’s 45,000 employees ensure that patients have access to innovative products and medical devices in our therapy areas of central nervous system disorders, endocrinology, nephrology, gastroenterology and oncology.
www.otsuka-europe.com
www.otsuka-us.com

 

   Otsuka

RECORDATI S.p.A
Stand number: 8

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is committed to the research and development of new specialties within cardiology, psychiatric and urogenital therapeutic area and of treatments for rare diseases.
www.recordati.com

 

   Recordati
Saladax Biomedical
Expert science exchange session: CE.01


Saladax develops rapid blood tests to measure levels of antipsychotic drug in a patient. These tests will enable psychiatrists to better assess adherence and better adjust dosing. The Saladax MyCare Psychiatry line will provide antipsychotic drug levels for greater insight into patient adherence and possible treatment failures. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2003 certified.
www.MyCareTests.com
www.saladax.com
 
  Saladax 
Schwabe Group
Stand number: 2
Satellite symposium: C.11


The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the Group focus on plants as the basis for developing pharmaceuticals and health products. The original form of the Group’s parent company, which is now Dr. Willmar Schwabe GmbH & Co. KG, is one of the oldest pharmaceutical manufacturers in Europe and has a company history dating back over 150 years.
www.schwabe-group.com
 
   Schwabe

SERVIER
Stand number: 7
Satellite symposium: C.07

Servier is an international independent pharmaceutical company governed by a non-profit foundation. Neuropsychiatry is one of the fifth therapeutic areas where research and development of innovative therapeutic solutions for patients are concentrated. Agomelatine is approved since 2009 for the treatment of depression. Multiple sclerosis and autism spectrum disorders are also areas of interest for Servier.
www.servier.com

 

   SERVIER

Shire
Satellite symposium: C.08

With more than 20 years of experience, Shire is a global leader in ADHD education and treatment innovation. We are committed to raising awareness of this impairing psychiatric disorder through engagement with physicians, patients and caregivers.
Shire enable people with life-altering conditions in specialty and rare diseases to live their lives to the fullest. We work tirelessly to develop breakthrough medicines that have a meaningful impact on these patients and all who support them on their journey.
Our diverse capabilities enable us to reach patients in over 100 countries across therapeutic areas such as neuroscience, rare diseases, haematology and immunology.
www.shire.com

 

  ShireGME

Sumitomo Dainippon Pharma Co., Ltd.
Satellite symposium: C.09

Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US. Sumitomo Dainippon Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan operating globally.
www.ds-pharma.com

 

  Sumitomo

Sunovion Pharmaceuticals Europe
Stand number: 9
Satellite symposium: C.09


Sunovion Pharmaceuticals Europe, headquartered in London, is a wholly owned subsidiary of Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is headquartered in Marlborough, Massachusetts, US.
www.sunovion.eu.

 

   Sunovion